Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway

Molecular Therapy

Volumn 22, Issue 7, 2014, Pages 1310-1319

  Blanco, Elvin ^a   Sangai, Takafumi ^b   Wu, Suhong ^a   Hsiao, Angela ^a   Ruiz Esparza, Guillermo U ^a,c   Gonzalez Delgado, Carlos A ^a,c   Cara, Francisca E ^a   Granados Principal, Sergio ^d   Evans, Kurt W ^b   Akcakanat, Argun ^b   Wang, Ying ^b   Do, Kim Anh ^b   Meric Bernstam, Funda ^b   Ferrari, Mauro ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c ESCUELA DE MEDICINA Y CIENCIAS DE LA SALUD   (Mexico)

^d HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; NANOPARTICLE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG TUMOR LEVEL; FEMALE; IN VITRO STUDY; LIVER; MOUSE; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SPLEEN; ANIMAL; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; HUMAN; MAMMARY NEOPLASMS, ANIMAL; MCF 7 CELL LINE; METABOLISM; NUDE MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALIA; MUS;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MCF-7 CELLS; MICE; MICE, NUDE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84903759913     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.27     Document Type: Conference Paper

References (50)

1. Calvo, E, Bolós, V and Grande, E (2009). Multiple roles and therapeutic implications of Akt signaling in cancer. Onco Targets Ther 2: 135-150
2. Carraway, H and Hidalgo, M (2004). New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 6: 219-224
3. Meric-Bernstam, F and Gonzalez-Angulo, AM (2009). Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27: 2278-2287
4. Dancey, J (2010). Mtor signaling and drug development in cancer. Nat Rev Clin Oncol 7: 209-219
5. Noh, WC, Mondesire, WH, Peng, J, Jian, W, Zhang, H, Dong, J et al. (2004). Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10: 1013-1023. (Pubitemid 38198903
6. Ellard, SL, Clemons, M, Gelmon, KA, Norris, B, Kennecke, H, Chia, S et al. (2009). Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 27: 4536-4541
7. Fleming, GF, Ma, CX, Huo, D, Sattar, H, Tretiakova, M, Lin, L et al. (2012). Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat 136: 355-363
8. Fung, AS, Wu, L and Tannock, IF (2009). Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clin Cancer Res 15: 5389-5395
9. Mondesire, WH, Jian, W, Zhang, H, Ensor, J, Hung, MC, Mills, GB et al. (2004). Targeting mammalian target of rapamycin synergistically enhances chemotherapyinduced cytotoxicity in breast cancer cells. Clin Cancer Res 10: 7031-7042. (Pubitemid 39383055
10. Gonzalez-Angulo, AM, Green, MC, Murray, JL, Palla, SL, Koenig, KH, Brewster, AM et al. (2011). Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptornegative breast cancer (TNBC). J Clin Oncol 29: (suppl; abstr 1016
11. Green, MR, Manikhas, GM, Orlov, S, Afanasyev, B, Makhson, AM, Bhar, P et al. (2006). Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 17: 1263-1268. (Pubitemid 44288216
12. Davis, ME, Chen, ZG and Shin, DM (2008). Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov 7: 771-782
13. Ferrari, M (2005). Cancer nanotechnology: Opportunities and challenges. Nat Rev Cancer 5: 161-171. (Pubitemid 40314948
14. Torchilin, V (2011). Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63: 131-135
15. Cabral, H, Nishiyama, N and Kataoka, K (2011). Supramolecular nanodevices: From design validation to theranostic nanomedicine. Acc Chem Res 44: 999-1008
16. Zhao, B, Wang, XQ, Wang, XY, Zhang, H, Dai, WB, Wang, J et al. (2013). Nanotoxicity comparison of four amphiphilic polymeric micelles with similar hydrophilic or hydrophobic structure. Part Fibre Toxicol 10: 47
17. Chou, TC and Talalay, P (1984). Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55
18. Sangai, T, Akcakanat, A, Chen, H, Tarco, E, Wu, Y, Do, KA et al. (2012). Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res 18: 5816-5828
19. Peer, D, Karp, JM, Hong, S, Farokhzad, OC, Margalit, R and Langer, R (2007). Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2: 751-760. (Pubitemid 350223348
20. Meric-Bernstam, F, Akcakanat, A, Chen, H, Do, KA, Sangai, T, Adkins, F et al. (2012). PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 18: 1777-1789
21. O'Reilly, KE, Rojo, F, She, QB, Solit, D, Mills, GB, Smith, D et al. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508. (Pubitemid 43259931
22. Sun, SY, Rosenberg, LM, Wang, X, Zhou, Z, Yue, P, Fu, H et al. (2005). Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65: 7052-7058. (Pubitemid 41161231
23. O'Brien, ME, Wigler, N, Inbar, M, Rosso, R, Grischke, E, Santoro, A et al.; CAELYX Breast Cancer Study Group. (2004). Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15: 440-449. (Pubitemid 38444547
24. Kim, TY, Kim, DW, Chung, JY, Shin, SG, Kim, SC, Heo, DS et al. (2004). Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelleformulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10: 3708-3716. (Pubitemid 38697604
25. Winer, EP, Berry, DA, Woolf, S, Duggan, D, Kornblith, A, Harris, LN et al. (2004). Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and leukemia group B trial 9342. J Clin Oncol 22: 2061-2068. (Pubitemid 41095138
26. Blanco, E, Bey, EA, Khemtong, C, Yang, SG, Setti-Guthi, J, Chen, H et al. (2010). Betalapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res 70: 3896-3904
27. Yamamoto, Y, Nagasaki, Y, Kato, Y, Sugiyama, Y and Kataoka, K (2001). Longcirculating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. J Control Release 77: 27-38. (Pubitemid 33022613
28. Chen, H, Kim, S, He, W, Wang, H, Low, PS, Park, K et al. (2008). Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo forster resonance energy transfer imaging. Langmuir 24: 5213-5217
29. Murphy, JE (2011). Clinical Pharmacokinetics. American Society of Health-System Pharmacists: Bethesda
30. Paál, K, Müller, J and Hegedûs, L (2001). High affinity binding of paclitaxel to human serum albumin. Eur J Biochem 268: 2187-2191. (Pubitemid 32852961
31. Maeda, H (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41: 189-207
32. Lim, WT, Tan, EH, Toh, CK, Hee, SW, Leong, SS, Ang, PC et al. (2010). Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. Ann Oncol 21: 382-388
33. Xiao, K, Luo, J, Li, Y, Lee, JS, Fung, G and Lam, KS (2011). PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. J Control Release 155: 272-281
34. Kaminskas, LM, McLeod, VM, Kelly, BD, Sberna, G, Boyd, BJ, Williamson, M et al. (2012). A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomedicine 8: 103-111
35. Faried, LS, Faried, A, Kanuma, T, Nakazato, T, Tamura, T, Kuwano, H et al. (2006). Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel. Eur J Cancer 42: 934-947
36. Haritunians, T, Mori, A, O'Kelly, J, Luong, QT, Giles, FJ and Koeffler, HP (2007). Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21: 333-339. (Pubitemid 46158128
37. Campone, M, Levy, V, Bourbouloux, E, Berton Rigaud, D, Bootle, D, Dutreix, C et al. (2009). Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer 100: 315-321
38. Sessa, C, Tosi, D, Viganò, L, Albanell, J, Hess, D, Maur, M et al. (2010). Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann Oncol 21: 1315-1322
39. Dong, J, Peng, J, Zhang, H, Mondesire, WH, Jian, W, Mills, GB et al. (2005). Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res 65: 1961-1972. (Pubitemid 40478626
40. VanderWeele, DJ, Zhou, R and Rudin, CM (2004). Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther 3: 1605-1613. (Pubitemid 40136716
41. Sunters, A, Madureira, PA, Pomeranz, KM, Aubert, M, Brosens, JJ, Cook, SJ et al. (2006). Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-Terminal kinase and Akt. Cancer Res 66: 212-220. (Pubitemid 43166027
42. Blanco, E, Bey, EA, Dong, Y, Weinberg, BD, Sutton, DM, Boothman, DA et al. (2007). Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. J Control Release 122: 365-374. (Pubitemid 47404665
43. Alexis, F, Venkatraman, SS, Rath, SK and Boey, F (2004). In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices. J Control Release 98: 67-74. (Pubitemid 38881608
44. Sutton, D, Wang, S, Nasongkla, N, Gao, J and Dormidontova, EE (2007). Doxorubicin and beta-lapachone release and interaction with micellar core materials: Experiment and modeling. Exp Biol Med (Maywood) 232: 1090-1099. (Pubitemid 47358192
45. Moreno, A, Akcakanat, A, Munsell, MF, Soni, A, Yao, JC and Meric-Bernstam, F (2008). Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 15: 257-266. (Pubitemid 351449744
46. Saal, LH, Johansson, P, Holm, K, Gruvberger-Saal, SK, She, QB, Maurer, M et al. (2007). Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 104: 7564-7569. (Pubitemid 47185946
47. Stemke-Hale, K, Gonzalez-Angulo, AM, Lluch, A, Neve, RM, Kuo, WL, Davies, M et al. (2008). An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084-6091
48. Vasudevan, KM, Barbie, DA, Davies, MA, Rabinovsky, R, McNear, CJ, Kim, JJ et al. (2009). AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16: 21-32
49. Pounds, S and Morris, SW (2003). Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics 19: 1236-1242. (Pubitemid 36850216
50. Storey, JD (2002). A direct approach to false discovery rates. J Royal Statistical Society: Series B (Statistical Methodology) 64: 479-498.